- Home
- CISS vs XRTX Comparison
CISS vs XRTX Comparison
Compare CISS & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- XRTX
- Stock Information
- Founded
- CISS 2022
- XRTX 2011
- Country
- CISS Greece
- XRTX Canada
- Employees
- CISS N/A
- XRTX N/A
- Industry
- CISS Marine Transportation
- XRTX Pharmaceuticals and Biotechnology
- Sector
- CISS Consumer Discretionary
- XRTX Health Care
- Exchange
- CISS Nasdaq
- XRTX Nasdaq
- Market Cap
- CISS 3.0M
- XRTX 3.0M
- IPO Year
- CISS N/A
- XRTX N/A
- Fundamental
- Price
- CISS $0.58
- XRTX $0.92
- Analyst Decision
- CISS
- XRTX
- Analyst Count
- CISS 0
- XRTX 0
- Target Price
- CISS N/A
- XRTX N/A
- AVG Volume (30 Days)
- CISS 80.0K
- XRTX 16.7K
- Earning Date
- CISS 05-27-2025
- XRTX 05-16-2025
- Dividend Yield
- CISS N/A
- XRTX N/A
- EPS Growth
- CISS N/A
- XRTX N/A
- EPS
- CISS N/A
- XRTX N/A
- Revenue
- CISS $42,296,101.00
- XRTX N/A
- Revenue This Year
- CISS N/A
- XRTX N/A
- Revenue Next Year
- CISS N/A
- XRTX N/A
- P/E Ratio
- CISS N/A
- XRTX N/A
- Revenue Growth
- CISS 47.17
- XRTX N/A
- 52 Week Low
- CISS $0.48
- XRTX $0.82
- 52 Week High
- CISS $13.50
- XRTX $3.92
- Technical
- Relative Strength Index (RSI)
- CISS 30.12
- XRTX 45.74
- Support Level
- CISS $0.48
- XRTX $0.90
- Resistance Level
- CISS $0.74
- XRTX $1.10
- Average True Range (ATR)
- CISS 0.05
- XRTX 0.08
- MACD
- CISS 0.00
- XRTX -0.01
- Stochastic Oscillator
- CISS 37.27
- XRTX 10.50
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.